{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:17:55Z","timestamp":1769602675057,"version":"3.49.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jtct.2024.01.058","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T16:03:07Z","timestamp":1706716987000},"page":"126-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["CARving a Path Forward: Unveiling T Cell Phenotypes Across the Spectrum of Multiple Myeloma Disease Progression to Inform Future Strategies for Overcoming Resistance to CAR T Therapy"],"prefix":"10.1016","volume":"30","author":[{"given":"Christopher J.","family":"Ferreri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2024.01.058_bib0001","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jtct.2024.01.058_bib0002","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.jtct.2024.01.058_bib0003","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jtct.2024.01.058_bib0004","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jtct.2024.01.058_bib0005","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1158\/2643-3230.BCD-20-0227","article-title":"Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple Myeloma","volume":"2","author":"van de Donk","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.jtct.2024.01.058_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtct.2024.01.058_bib0007","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2024.01.058_bib0008","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti\u2013B-Cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jtct.2024.01.058_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.11.014","article-title":"PD1+TIGIT+2B4+KLRG1+ Cells Might Underlie T Cell Dysfunction in Patients Treated with BCMA-Directed Chimeric Antigen Receptor T Cell Therapy","author":"Mishra","year":"2024","journal-title":"Transplantation and Cellular Therapy"},{"key":"10.1016\/j.jtct.2024.01.058_bib0010","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127807","article-title":"Early alterations in stem-like\/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy","volume":"4","author":"Bailur","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jtct.2024.01.058_bib0011","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"Journal of Clinical Investigation"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2024.01.058_bib0012","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-137650","article-title":"Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy","volume":"136","author":"Leblay","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.01.058_bib0013","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood.2021011597","article-title":"PI3K\u03b4\/\u0263 inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity","volume":"139","author":"Funk","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2024.01.058_bib0014","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2020-140410","article-title":"Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes","volume":"136","author":"Alsina","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2024.01.058_bib0015","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood-2022-160038","article-title":"Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633\/BMS-986354 in Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"140","author":"Costa","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.01.058_bib0016","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/bjh.17397","article-title":"B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy","volume":"193","author":"Bernabei","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2024.01.058_bib0017","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy","volume":"141","author":"Van Oekelen","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.01.058_bib0018","article-title":"CD3+CD4-CD8- (Double-Negative) T Cells in Inflammation, Immune Disorders and Cancer","volume":"13","author":"Wu","year":"2022","journal-title":"Frontiers in Immunology"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724001258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724001258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:12:09Z","timestamp":1763003529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724001258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2666636724001258"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.01.058","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CARving a Path Forward: Unveiling T Cell Phenotypes Across the Spectrum of Multiple Myeloma Disease Progression to Inform Future Strategies for Overcoming Resistance to CAR T Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.01.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}